Literature DB >> 3338018

Characterization and comparison of two newly established Epstein-Barr virus-negative lymphoma B-cell lines. Surface markers, growth characteristics, cytogenetics, and transplantability.

M Abe1, Y Nozawa, H Wakasa, H Ohno, S Fukuhara.   

Abstract

Two Epstein-Barr virus (EBV)-negative lymphoma B-cell lines, HBL-1 and HBL-2, were established from a pleural effusion and a lymph node biopsy of two patients with diffuse large cell lymphoma. HBL-1 and HBL-2 showed the characteristics of activated B-cells in B-cell lineage, as did original lymphoma cells. Chromosome analyses revealed that HBL-1 exhibiting 14q+ marker-positive lymphoid cancer showed a new subclass of 14q32 translocation resulting from a translocation between chromosomes 14 and 16, which had been masked in a complex translocation involving five chromosomes, and that HBL-2 had a 14q+ marker chromosome, the result of an 11;14 translocation [t(11;14)(q13;32)]. Successful heterotransplantation into athymic nude mice demonstrated tumorigenicity of HBL-1 and HBL-2. The transplantability and tumor growth rate of HBL-2 were higher and more rapid than those of HBL-1. HBL-1 and HBL-2 appear useful for facilitating therapeutic investigations as well as immunologic and oncogenic studies in B-cell lymphomas.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3338018     DOI: 10.1002/1097-0142(19880201)61:3<483::aid-cncr2820610313>3.0.co;2-l

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

Review 1.  Molecular pathology of low grade malignant lymphomas.

Authors:  H Ratech
Journal:  Med Oncol       Date:  1995-09       Impact factor: 3.064

2.  Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms.

Authors:  Yibin Yang; Roland Schmitz; Joseph Mitala; Amanda Whiting; Wenming Xiao; Michele Ceribelli; George W Wright; Hong Zhao; Yandan Yang; Weihong Xu; Andreas Rosenwald; German Ott; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Rita M Braziel; Raymond R Tubbs; James R Cook; Dennis D Weisenburger; Wing C Chan; Adrian Wiestner; Michael J Kruhlak; Kazuhiro Iwai; Federico Bernal; Louis M Staudt
Journal:  Cancer Discov       Date:  2014-02-03       Impact factor: 39.397

3.  p53 mutation in B-cell lymphoid neoplasms with reference to oncogene rearrangements associated with chromosomal translocations.

Authors:  T Akasaka; M Muramatsu; N Kadowaki; H Ohno; K Ishizaki; H Yamabe; S Fukuhara; M Okuma
Journal:  Jpn J Cancer Res       Date:  1996-09

4.  Specific interactions of BCL-2 family proteins mediate sensitivity to BH3-mimetics in diffuse large B-cell lymphoma.

Authors:  Victoria M Smith; Anna Dietz; Kristina Henz; Daniela Bruecher; Ross Jackson; Lisa Kowald; Sjoerd J L van Wijk; Sandrine Jayne; Salvador Macip; Simone Fulda; Martin J S Dyer; Meike Vogler
Journal:  Haematologica       Date:  2019-10-10       Impact factor: 9.941

5.  Transvection mediated by the translocated cyclin D1 locus in mantle cell lymphoma.

Authors:  Hui Liu; Jing Huang; Jin Wang; Shuguang Jiang; Alexis S Bailey; Devorah C Goldman; Markus Welcker; Victoria Bedell; Marilyn L Slovak; Bruce Clurman; Mathew Thayer; William H Fleming; Elliot Epner
Journal:  J Exp Med       Date:  2008-07-14       Impact factor: 14.307

6.  Purine analog-like properties of bendamustine underlie rapid activation of DNA damage response and synergistic effects with pyrimidine analogues in lymphoid malignancies.

Authors:  Nobuya Hiraoka; Jiro Kikuchi; Takahiro Yamauchi; Daisuke Koyama; Taeko Wada; Mitsuyo Uesawa; Miyuki Akutsu; Shigehisa Mori; Yuichi Nakamura; Takanori Ueda; Yasuhiko Kano; Yusuke Furukawa
Journal:  PLoS One       Date:  2014-03-13       Impact factor: 3.240

7.  MALT1 auto-proteolysis is essential for NF-κB-dependent gene transcription in activated lymphocytes.

Authors:  Mathijs Baens; Luca Bonsignore; Riet Somers; Charlotte Vanderheydt; Stephen D Weeks; Jenny Gunnarsson; Ewa Nilsson; Robert G Roth; Margot Thome; Peter Marynen
Journal:  PLoS One       Date:  2014-08-08       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.